Moberg Pharma Extends Distribution Agreement with Menarini

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 9, 2015 at 2:45 AM

Moberg Pharma Extends Distribution Agreement with Menarini Group for Emtrix to Russia

STOCKHOLM, February 9, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that Berlin-Chemie AG, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Emtrix® in Russia and Ukraine. The extended distribution agreement builds on an existing collaboration between Moberg and Menarini, which resulted in a successful launch of Emtrix® in Italy and most recently, the expansion to China and Southeast Asia where product launches have been initiated. The rights to Emtrix® in Russia were released from a previous distribution agreement with Meda AB. The product was not launched in Russia under the previous agreement. Berlin-Chemie/Menarini is a leading regional biopharmaceutical company with full national coverage in Russia, a sales force with more than 700 sales representatives and a strong track record of launching and promoting Consumer Health brands. The global sales of the Menarini Group exceed 3.3 billion Euros. Russia and Ukraine comprise almost 200 million people and represent a significant long-term growth opportunity for Moberg Pharma. “I am very pleased to expand our collaboration with the Menarini Group through this agreement with Berlin-Chemie – a leading marketer in Eastern Europe. The Russian market has significant long-term potential for Moberg’s products,” said Peter Wolpert, CEO of Moberg Pharma AB. “We look forward to introducing Emtrix® to consumers in Russia. The product has potential to contribute strongly to our expansion within the Consumer Health market, as it provides rapid relief for a large segment of patients suffering from nail fungus”, said Michael Sirotovich, COO at Berlin-Chemie AG’s International Division. About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 am (CET) on February 9, 2015. About Emtrix® and nail disease Emtrix is a topical treatment used to treat nail disease. Launched in late 2010, it quickly became the market leader in the Nordics and recently also the best -selling product in its category in the U.S. The international launch is under way via a proprietary sales organization in the U.S. and ten partners that hold rights for 50 markets, including the major EU markets, China, Turkey and Russia. Emtrix is a prescription-free, over-the-counter product sold under the names Kerasal Nail®, Naloc™/Nalox™ and Emtrix®. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Emtrix has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease. The condition afflicts approximately 10 percent of the population and is more common among the elderly. It is generally recognized that there is a need for new efficacious and safe topical treatments. For additional information, please contact: Peter Wolpert, CEO, Phone: +46 (0)70 - 735 71 35, E-mail: peter.wolpert@mobergpharma.se Anna Ljung, CFO, Phone: +46 (0)70 – 766 60 30, Email: anna.ljung@mobergpharma.se About Moberg Pharma Moberg Pharma AB (MOB.ST) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail®(Nalox™/ Emtrix®in certain markets outside the U.S.) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The strategy to expand the portfolio includes acquisitions and in -licensing, as well as internal development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com. About Menarini Group The Menarini Group is the number one Italian pharmaceutical company in the world, 16th in Europe out of 5,291 companies, and 36th company in the world out of 19,042 companies, with a turnover of more than 3,3 billion Euro and more than 16,600 employees. The Menarini Group has always pursued two strategic objectives: Research and Internationalisation and is present in the most important therapeutic areas including products for cardiology, gastroenterology, pneumology/antibiotics, diabetology, antinflammatory agents/analgesics. With 14 production sites and 5 Research and Development centres, the Menarini Group has a strong presence throughout Europe and Asia, Africa, Central and South America. Menarini’s products are available in more than 100 countries worldwide. For further information please visit www.menarini.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Curaleaf Expands in Florida Amid Rising Cannabis Demand

Curaleaf's Bold Moves in Florida's Ganja Gold Rush Fresh out of the gate, Curaleaf is saddling up for a wild ride into Florida's cannabis frontier. They've just thrown open the doors of their latest dispensary in Riverview, cranking their statewide count up to 77. Now, isn’t that something? If you're tracking these folks, you know that bringing their nationwide total to...

Photronics Investors Must Act by Sept. 4, 2026 Deadline

Action Time for Photronics Investors There's nothing like a looming deadline to get the adrenaline pumping, especially when you're staring down the barrel of a federal securities class action. Photronics, Inc. (NASDAQ: PLAB) has found itself tangled in legal webs, with the clock ticking down to September 4, 2026. That’s the deadline for investors to move on being the...

SimpliTrain's Momentum in LMS Market Heating Up

SimpliTrain Finds its Groove in the LMS Arena Out here in Delray Beach, SimpliTrain's making waves in the Learning Management System (LMS) market, recently snagging the 'Pervasive Player' tag from MarketsandMarkets' 360Quadrants platform. This cloud-based learning powerhouse ain't just playing around; they're doubling down with expansion into AI and other fancy tech bits...

King Risk Partners Expands Mid-Atlantic Presence Boldly

King Risk Partners Grows with New Jersey Acquisition You don't get far in the insurance game without making some bold moves, and King Risk Partners just made a big one—sweeping into New Jersey. They've snagged Conover Beyer Associates Insurance, a firm that's been around longer than some European countries. It's not every day you buy a piece of history, but that's...

Exemplar Luxury Group Taps Gretchen Koback Pursel

Changing the Game with a New Chief People Officer There’s an old saying in retail: talent rules everything. Well, Exemplar Luxury Group is doubling down on this with its appointment of Gretchen Koback Pursel as Chief People Officer. Set to take the reins on September 28, Pursel brings an impressive resume chock-full of luxury and innovative transformations from big...

Megan Holdings Investors Face Deadline for Class Action

Forgive my bluntness, but if you've been snoozing on your Megan Holdings Limited (NASDAQ:MGN) shares, it's time to wake up and smell the lawsuit papers. They're flying around faster than news at a market crash. If you snagged those shares between September 26, 2025, and March 25, 2026, or got in during the IPO on September 26, 2025, here's the deal: the deadline looms on...

Aurzen Leverages Basquiat for Art-Infused Projection Line

A Fresh Perspective on Portable Projection If anyone had told me a tech brand would buddy up with the world of fine art to launch a new gadget line, I'd have raised an eyebrow. But here we are, shrugging away the standard and looking at what's cooking over at Aurzen. The company's new initiative, 'Unfold the Art,' marries the magnetism of Jean-Michel Basquiat's artwork...

Reolink Unveils OMVI 2i Ultra at IFA 2026

Reolink's Bold Move Into the Future of Home Security Amidst the hustle of Berlin's IFA 2026, Reolink dropped its latest gem: the OMVI 2i Ultra—an all-in-one security powerhouse promising to change the game for home protection junkies. As usual, Reolink's got its eyes on the prize, pushing boundaries with this latest lineup. OMVI 2i Ultra: Dual-View Revolution If you've...

PerfectVape Unveils Online Deals Amid Vape Craze

PerfectVape's Digital Bargain Bonanza Alright, so you think you've seen savings? Well, PerfectVape's throwing a real bone to those hunting for vape deals online. They're slapping 10% off on select disposable vapes—no strings, just a promo code, PV10, you punch in at checkout. We've got ourselves an internet-era sale without needing to elbow through crowds. Browsing Made...

Transamerica Reinforces Leadership for Retirement Expansion

Transamerica's Next Phase: Leadership Moves in Retirement Transamerica just pulled a move that’s both bold and calculated. They’ve beefed up their retirement distribution squad with Danny Kling and Kevin Murphy stepping into the spotlight. These guys are bringing heaps of experience and a fresh jolt of energy to keep the momentum going. No doubt this is Transamerica...